Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases

Summary

Eli Lilly announced an acquisition of Merida Biosciences to advance treatments for autoimmune and allergic diseases using Merida's antibody-engineering platform. Initial Phase 1 data for MER511 demonstrated robust reductions in pathogenic thyroid-stimulating antibodies with a favorable safety profile.